X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FULFORD INDIA NATCO PHARMA/
FULFORD INDIA
 
P/E (TTM) x 30.8 398.8 7.7% View Chart
P/BV x 23.4 6.2 375.9% View Chart
Dividend Yield % 0.5 0.1 578.6%  

Financials

 NATCO PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FULFORD INDIA
Mar-14
NATCO PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs877942 93.1%   
Low Rs424450 94.1%   
Sales per share (Unadj.) Rs223.4691.4 32.3%  
Earnings per share (Unadj.) Rs31.111.5 271.1%  
Cash flow per share (Unadj.) Rs40.315.4 262.2%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.3 267.6%  
Book value per share (Unadj.) Rs219.5380.0 57.8%  
Shares outstanding (eoy) m33.073.90 847.9%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.0 289.1%   
Avg P/E ratio x20.960.7 34.5%  
P/CF ratio (eoy) x16.145.3 35.6%  
Price / Book Value ratio x3.01.8 161.7%  
Dividend payout %16.117.4 92.2%   
Avg Mkt Cap Rs m21,5042,714 792.2%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m1,128505 223.3%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m7,3892,696 274.0%  
Other income Rs m167125 133.3%   
Total revenues Rs m7,5562,822 267.8%   
Gross profit Rs m1,793-46 -3,864.9%  
Depreciation Rs m30415 2,002.6%   
Interest Rs m36610 3,854.7%   
Profit before tax Rs m1,29054 2,375.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m30910 3,215.6%   
Profit after tax Rs m1,02745 2,298.4%  
Gross profit margin %24.3-1.7 -1,410.4%  
Effective tax rate %23.917.7 135.4%   
Net profit margin %13.91.7 838.8%  
BALANCE SHEET DATA
Current assets Rs m3,6811,738 211.8%   
Current liabilities Rs m3,123545 573.3%   
Net working cap to sales %7.644.3 17.1%  
Current ratio x1.23.2 36.9%  
Inventory Days Days8948 184.6%  
Debtors Days Days594 1,363.3%  
Net fixed assets Rs m7,68512 64,581.5%   
Share capital Rs m33139 847.9%   
"Free" reserves Rs m6,6701,443 462.2%   
Net worth Rs m7,2591,482 489.8%   
Long term debt Rs m9550-   
Total assets Rs m11,9572,077 575.8%  
Interest coverage x4.56.7 67.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 47.6%   
Return on assets %11.72.6 446.6%  
Return on equity %14.23.0 469.3%  
Return on capital %20.74.3 481.4%  
Exports to sales %39.40-   
Imports to sales %5.724.5 23.3%   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421659 63.9%   
Fx inflow Rs m3,44517 20,031.4%   
Fx outflow Rs m703673 104.4%   
Net fx Rs m2,743-656 -418.1%   
CASH FLOW
From Operations Rs m1,44090 1,600.3%  
From Investments Rs m-1,089105 -1,041.3%  
From Financial Activity Rs m-353-14 2,501.4%  
Net Cashflow Rs m-1181 -0.8%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 3.8 206.3%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.2 122.6%  
Shareholders   25,395 4,783 530.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS